Daiichi Sankyo Announces Launch of Oxycodone Extended Release Tablets NX “Daiichi Sankyo” for Sustained Cancer Pain Treatment in Japan

Tokyo, Japan (September 12, 2019) - Daiichi Sankyo Company Limited (hereafter, Daiichi Sankyo) today announced it has launched a new generic formulation of oxycodone hydrochloride hydrate extended release tablets for sustained cancer pain treatment in Japan: Oxycodone Extended Release Tablets 5 mg, 10 mg, 20 mg and 40 mg NX "Daiichi Sankyo" (hereafter, new formulation).

The new formulation of oxycodone hydrochloride, a strong opioid analgesic providing relief of moderate to severe pain in various types of cancer, contains the narcotic antagonist naloxone in order to prevent abuse.

It is manufactured from drug substance to formulation solely by Daiichi Sankyo's subsidiary in Japan, Daiichi Sankyo Propharma Co., Ltd. (marketing authorization holder).

The addition of the new formulation to our product lineup of opioid analgesics will provide another treatment option to patients suffering from cancer pain and further enhance our contribution to healthcare in Japan.

<Product Summary>

Product Name



Original Brand Name

Oxycodone Extended Release Tablets 5mg NX "Daiichi Sankyo"

Oxycodone Extended Release Tablets 10mg NX "Daiichi Sankyo"

Oxycodone Extended Release Tablets 20mg NX "Daiichi Sankyo"

Oxycodone Extended Release Tablets 40mg NX "Daiichi Sankyo"

Sustained cancer

pain treatment

OxyContin® TR Tablets 5 mg

OxyContin® TR Tablets 10 mg

OxyContin® TR Tablets 20 mg

OxyContin® TR Tablets 40 mg

About Daiichi Sankyo Opioid Analgesics in Japan

Daiichi Sankyo aims to contribute to the total care of cancer patients for their lives with our opioid analgesics.

Daiichi Sankyo believes that expanding our product lineup of opioid analgesics provides support for patients living with cancer by improving their quality of life through pain relief.

Opioid analgesics sold in Japan by Daiichi Sankyo comprise the hydromorphone hydrochloride formulations Narusus® Tablets (extended release formulation), Narurapid® Tablets (immediate release formulation), Naruvein® Injection (injection formulation), the oxycodone hydrochloride formulations Oxycodone Extended Release Tablets "Daiichi Sankyo" (extended release formulation) and Oxycodone Extended Release Tablets NX "Daiichi Sankyo" (extended release formulation) that have just been launched, Oxycodone Tablets "Daiichi Sankyo" (extended release formulation) and Oxycodone Injections "Daiichi Sankyo"(injection formulation) as well as the fentanyl citrate tape formulation Fetanyl Citrate Tape for 1 day "Daiichi Sankyo" (transdermal absorption formulation).

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.

To read more Press Release articles, click here.